Alder Biopharmaceuticals Inc. Garners $40,000,000 Series C Financing Round

  • Feed Type
  • Date
    1/11/2008
  • Company Name
    Alder Biopharmaceuticals Inc.
  • Mailing Address
    11804 North Creek Parkway South Bothell, WA 98011
  • Company Description
    Alder Biopharmaceuticals uniquely identifies, develops, and manufactures novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas. Alder’s management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics.
  • Website
    http://www.alderbio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $40,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    Alder plans to use the financing to advance its lead programs through human clinical trials and to continue to advance its proprietary Mab Xpress yeast antibody production technology.
  • M&A Terms
  • Venture Investor
    Delphi Ventures
  • Venture Investor
    TPG – Texas Pacific Group Ventures
  • Venture Investor
    Sevin Rosen Funds
  • Venture Investor
    Ventures West
  • Venture Investor
    H.I.G. Ventures
  • Venture Investor
    WRF Capital

Trending on Xconomy